George Eliades, PhD joined Mythic Therapeutics in April 2024 as President and Chief Executive Officer, bringing over 20 years of combined experience in corporate strategy, business development, and global management consulting in the biopharmaceutical industry. Prior to joining Mythic, George served as the Senior Vice President of Corporate Development and Chief Transformation Officer at Jazz Pharmaceuticals. In this role, he successfully led the acquisition of development and commercial rights for two clinical programs, the multi-billion dollar acquisition and integration of GW Pharmaceuticals, and the licensing agreement for zanidatamab, an investigational HER2-targeted bispecific antibody. Before that, he spent over 20 years at Bain & Company and Monitor Group, advising biotech clients in corporate strategy, M&A, growth, and digital-driven transformations. Dr. Eliades served nine years on the board of directors of the Pulmonary Fibrosis Foundation, including six years as board chair. He received a B.A. from Harvard College, where he graduated magna cum laude with highest honors, and an M.A. and a Ph.D. from Harvard University.